Auto-generated from public data. Not the firm's stated position.
BioMedPartners appears to focus on early-stage biotech investments, particularly in therapeutic areas including oncology, infectious disease, and immunotherapy, with a disclosed check size around €3.0M and a portfolio concentrated in companies developing novel drug candidates rather than fintech applications.
Generated 16 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Auto-detected from BioMedPartners's website.
Long-standing European VC career with involvement in numerous financing rounds and trade sales, previously Head of Life Sciences at NRW.BANK.
Serial entrepreneur with 25+ years building biotech companies, CEO of Cardior Pharmaceuticals acquired by Novo Nordisk for 1.025 billion EUR.
Biotech entrepreneur and antibody engineer, co-founder and former CEO of Numab Therapeutics, co-founded Yellow Jersey acquired by J&J.
Strong pharmaceutical and VC background, joined BioMedPartners in 2004, previously Venture Partner at MPM Capital and VP at Roche.
Experienced life science entrepreneur who built multiple startups, founder of GlycoVaxyn acquired by GSK for $212 million in 2015.
Entrepreneurial biotech leader with extensive experience in rare metabolic diseases, co-founder and CEO of Azafaros.
Private investor and board member in life science startups for 15+ years, founded VP Venture Partners AG in 2020.
Strong experience in valuation of early-stage life science companies, with BioMedPartners since inception in 2003.
Focus and check size from the firm's website. Website reachable as of Aug 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.